Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

Sponsor
Maastricht University Medical Center
Study ID
NCT06401824
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Brain Metastases, Adult
  • NSCLC Stage IV

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study will evaluate whether the combination of sacituzumab govitecan (SG) and bevacizumab will result in shrinkage of brain metastases from patients with non-squamous non-small cell lung cancer (NSCLC), with disease progression on chemotherapy and immunotherapy.

Key Dates

First listed
May 7, 2024
Start date
Apr 24, 2025
Status verified
May 2025
Primary completion
Nov 1, 2026
Completion
Apr 1, 2027

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: sacituzumab govitecan (SG) plus bevacizumab
    SG 10mg/kg intravenous day 1 and day 8 of a 21-day cycle, + bevacizumab 15 mg/kg iv day 1 of a 21-day cycle till unacceptable toxicity or disease progression.

Primary Outcome Measure

brain metastases overall response rate (ORR) [ Time Frame: up to 24 months ]

Central Contacts

Related Studies